These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 15668084

  • 1. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes.
    Boehm BO, Vaz JA, Brøndsted L, Home PD.
    Eur J Intern Med; 2004 Dec; 15(8):496-502. PubMed ID: 15668084
    [Abstract] [Full Text] [Related]

  • 2. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study.
    Shestakova M, Sharma SK, Almustafa M, Min KW, Ayad N, Azar ST, Danciulescu R, Khutsoane D, Guler S.
    Curr Med Res Opin; 2007 Dec; 23(12):3209-14. PubMed ID: 18005503
    [Abstract] [Full Text] [Related]

  • 3. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes.
    Bebakar WM, Chow CC, Kadir KA, Suwanwalaikorn S, Vaz JA, Bech OM, BIAsp-3021 study group.
    Diabetes Obes Metab; 2007 Sep; 9(5):724-32. PubMed ID: 17593237
    [Abstract] [Full Text] [Related]

  • 4. Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes.
    Velojic-Golubovic M, Mikic D, Pesic M, Dimic D, Radenkovic S, Antic S.
    J Endocrinol Invest; 2009 Jan; 32(1):23-7. PubMed ID: 19337010
    [Abstract] [Full Text] [Related]

  • 5. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ.
    Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with Type 1 diabetes: a randomized double-blinded crossover study.
    Chen JW, Lauritzen T, Christiansen JJ, Jensen LH, Clausen WH, Christiansen JS.
    Diabet Med; 2005 Mar; 22(3):273-7. PubMed ID: 15717874
    [Abstract] [Full Text] [Related]

  • 7. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes.
    Home PD, Hallgren P, Usadel KH, Sane T, Faber J, Grill V, Friberg HH.
    Diabetes Res Clin Pract; 2006 Feb; 71(2):131-9. PubMed ID: 16054266
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ.
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of inhaled insulin (AERx iDMS) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1-year data from a randomized, parallel group trial.
    Moses RG, Bartley P, Lunt H, O'Brien RC, Donnelly T, Gall MA, Vesterager A, Wollmer P, Roberts A.
    Diabet Med; 2009 Mar; 26(3):260-7. PubMed ID: 19317821
    [Abstract] [Full Text] [Related]

  • 10. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 11. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
    Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, Shestakova M, Ayad NM, Guler S, Bech OM, PRESENT Study Group.
    Diabetes Obes Metab; 2008 Mar; 10(3):212-22. PubMed ID: 18269636
    [Abstract] [Full Text] [Related]

  • 12. Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes.
    Schmoelzer I, de Campo A, Pressl H, Stelzl H, Dittrich P, Oettl K, Wascher TC.
    Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):176-81. PubMed ID: 15789278
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart.
    Jacobsen LV, Søgaard B, Riis A.
    Eur J Clin Pharmacol; 2000 Aug; 56(5):399-403. PubMed ID: 11009049
    [Abstract] [Full Text] [Related]

  • 14. A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study.
    Thorisdottir RL, Parkner T, Chen JW, Ejskjaer N, Christiansen JS.
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):216-21. PubMed ID: 19175369
    [Abstract] [Full Text] [Related]

  • 15. Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70.
    Ohira M, Endo K, Oyama T, Yamaguchi T, Ban N, Kawana H, Nagayama D, Nagumo A, Saiki A, Murano T, Watanabe H, Miyashita Y, Shirai K.
    Metabolism; 2011 Jan; 60(1):78-85. PubMed ID: 20667560
    [Abstract] [Full Text] [Related]

  • 16. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K, Dornhorst A, Sreenan S.
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

  • 18. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 19. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J.
    Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
    [Abstract] [Full Text] [Related]

  • 20. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
    Gao Y, Guo XH, Vaz JA, PRESENT Study Group.
    Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.